Navigation Links
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Date:8/8/2008

share, compared with a net loss for the second quarter of 2007 of $4.8

million, or $0.07 per share. Net loss for the six months ended June

30, 2008 was $21.0 million, or $0.27 per share, compared with a net

loss of $8.2 million, or $0.11 per share, for the comparable period

last year.

-- Revenues for the second quarter of 2008 were $1.4 million, compared

with $709,000 for the second quarter of 2007. Revenues under

collaborative agreements for the second quarter of 2008 were $1.4

million, compared with $539,000 for the second quarter of 2007.

Revenues under collaborative agreements in 2008 primarily consisted of

the amortization of upfront fees received from Baxter and Roche of

$588,000 and research and development reimbursements from Baxter of

$554,000 and Roche of $210,000. Cumulase(R) product sales for the

second quarter of 2008 were $48,000, compared with $139,000 for the

second quarter of 2007.

-- Research and development expenses for the second quarter of 2008 were

$8.9 million, compared with $4.1 million for the second quarter of

2007, reflecting increased compensation expenses including share-based

compensation expenses, research and development spending on the

Company's Insulin, Bisphosphonates, and PEG PH20 clinical and

pre-clinical programs, and production costs associated with the

manufacturing scale-up of the Company's rHuPH20 enzyme.

-- Selling, general and administrative expenses for the second quarter of

2008 were $3.8 million, compared with $2.4 million for the second

quarter of 2007, reflecting increases in compensation expenses

including share-based compensation expenses, as well as higher legal

and facilities expenses compared with the prior-year quarter.

-- Cash and cash equivalents were $82.4 million as of Jun
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
2. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
8. Halozyme Therapeutics Amends Stockholder Rights Plan
9. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
10. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
11. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
(Date:12/15/2014)... 2014  Origin Agritech Limited (NASDAQ GS: SEED) (" Origin ... crop seeds in China , today announced ... 2014 ended September 30, 2014, before the market opens on ... a teleconference on January 8, 2015, at 8:00 a.m. ET ... discuss the results. To participate in the call, please dial ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... their big brothers and sisters: they have a large surface ... same time a small number of atoms. This can produce ... of nanomaterials can suddenly become bendy, for instance, or a ... reddish. , New method developed , The chemical and ...
... 2011 Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), ... manufacture and sale of enzyme and protein products for ... that it has launched FibreZyme® G200, a ... quality and improve the economics of various pulp and ...
... Coast Angels (TCA), the nation,s largest angel ... including 12 new deals and 19 follow-on investments in ... investment leadership. TCA raised over $40 million ... $6 million through direct TCA investment and approximately $33.9 ...
Cached Biology Technology:3-D nanoparticle in atomic resolution 2Dyadic International Launches High Performance Enzyme for Pulp and Paper Industry Using New C1 Production Platform 2Tech Coast Angels Funds 31 Deals in 2010 and Highlights Three Profitable Exits 2
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
(Date:11/15/2014)... Nov. 13, 2014  While we may still be a ... used in "Star Trek" to gain instant access to all ... work with smartphones and tablets for monitoring and measuring our ... world. This may seem a tad Orwellian to some, but ... some of these technological opportunities into their healthcare regime. ...
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2
... tool to combat the worsening malaria epidemic in many ... Pasteur in Paris) have completed the first human trial ... on the surface of the malaria parasite, with very ... in the international open-access medical journal PLoS Medicine, most ...
... Through the Human Genome Project, the HapMap Project and ... are modified in some diseases. More difficult to measure ... 'managers' of genes ?that control gene activity and might ... led by the Wellcome Trust Sanger Institute, together with ...
... whiff of food that has made them sick in the ... to prevent them from eating that food again. It's a ... that it occurs in a broad range of species. Even ... associated with foods that have made them ill. , ...
Cached Biology News:New methods offer insight into regulatory DNA 2Worms know bad food when they smell it 2Worms know bad food when they smell it 3Worms know bad food when they smell it 4
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Feline Rhinotracheitis Virus...
Rabbit anti-NFkB p105/p50 (Ser529) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: